NIH Suspends Production at Two Facilities Over Sterility Concerns
The National Institutes of Health has suspended production at two of its facilities following a contamination probe.
According to the agency, an investigation found that a National Cancer Institute laboratory conducting cell therapy production and a National Institute of Mental Health facility producing positron emission tomography materials were not in compliance with quality and safety standards.
The investigation was initiated in June 2015 after an FDA inspection of the NIH Clinical Center Pharmaceutical Development Section uncovered problems with facilities, equipment, procedures and training. The findings resulted in NIH’s closure of the section’s sterile production unit.
NIH said April 21 that there was no evidence of harm to patients, and it would not enroll any new patients in affected trials until the problems are resolved. — Michael Cipriano
Subscribe to Drug GMP Report NOW and save $200 off the regular one-year price of $1,045 — plus receive a FREE copy of our webinar CD, GAMP Classification for Pharma Equipment and Software Systems — a $287 value!
LINKS TO KEY DOCUMENTS — You get links to key documents that support DGR's articles such as draft and final guidances, Form 483s, warning letters, proposed rules, closeout letters and much more.
FDANEWS DRUG DAILY BULLETIN — This daily email alert brings you targeted FDA regulatory, legislative and business news briefs in the pharmaceutical and biologics industries.
ONLINE ACCESS — Consider our newsletter archive your personal library! Search your current issue — and hundreds of past issues — by keyword and relevancy.
Copyright ©2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing